Biocon Overview

  • Year Founded
  • 1978

Year Founded

  • Status
  • Public

  • Employees
  • 9,811

Employees

  • Stock Symbol
  • 532523

Stock Symbol

  • Investments
  • 20

  • Share Price
  • $3.88
  • (As of Thursday Closing)

Biocon General Information

Description

Biocon Ltd is a biopharmaceutical company engaged in the manufacture of biotechnology products, active pharmaceutical ingredients, and formulations, including biosimilar drugs for diabetes, oncology, autoimmune diseases, and ophthalmology, as well as research services. The Company focuses on the core therapeutic areas of diabetes, oncology and immunology. Its segments are Generics, Biosimilars, and CRDMO, with Biosimilars generating the maximum revenue. The Company also complies with Extended Producer Responsibility (EPR) obligations by integrating EPR considerations into packaging design, procurement practices, and vendor engagement processes. The Company generates a majority of its revenue from customers located in India, and the rest from Brazil, Singapore, and the rest of the world.

Contact Information

Website
www.biocon.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 20th KM, Hosur Road
  • Electronic City
  • Bengaluru, Karnataka 560100
  • India
+91 080
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
BOM
Corporate Office
  • 20th KM, Hosur Road
  • Electronic City
  • Bengaluru, Karnataka 560100
  • India
+91 080

Biocon Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biocon Stock Performance

As of 19-Nov-2026, Biocon’s stock price is $3.88. Its current market cap is $6.35B with 1.64B shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.88 $3.87 $3.36 - $4.65 $6.35B 1.64B 453K $0.03

Biocon Financials Summary

As of 30-Sep-2026, Biocon has a trailing 12-month revenue of $1.87B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 7,738,610 7,886,649 7,031,130 6,143,879
Revenue 1,865,216 1,898,958 1,780,120 1,714,762
EBITDA 366,343 368,251 514,752 471,953
Net Income 48,760 43,638 119,836 123,511
Total Assets 6,796,323 6,746,036 6,873,718 6,723,629
Total Debt 1,634,316 1,635,790 2,146,616 1,951,795
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biocon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biocon‘s full profile, request access.

Request a free trial

Biocon Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Biocon Ltd is a biopharmaceutical company engaged in the manufacture of biotechnology products, active pharmaceutical in
Drug Discovery
Bengaluru, India
9,811 As of 2026

Mumbai, India
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biocon Competitors (37)

One of Biocon’s 37 competitors is Lupin, a Corporation company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lupin Corporation Mumbai, India
Cipla Corporation Mumbai, India
GSK Corporation London, United Kingdom
Glenmark Pharmaceuticals Corporation Mumbai, India
Aurobindo Pharma Corporation Hyderabad, India
You’re viewing 5 of 37 competitors. Get the full list »

Biocon Patents

Biocon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026139792-A1 Peptide drugs in a reusable pen Pending 23-Dec-2024
WO-2025262552-A1 Purification of gip/ glp-1 dual agonist peptides Pending 17-Jun-2024
EP-4655312-A1 A process for the preparation of glucagon Pending 27-Jan-2023
US-20260042810-A1 A process for the preparation of glucagon Pending 27-Jan-2023
WO-2024157198-A1 A process for the preparation of glucagon Inactive 27-Jan-2023 C07K14/605
To view Biocon’s complete patent history, request access »

Biocon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biocon Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biocon‘s full profile, request access.

Request a free trial

Biocon Investments & Acquisitions (20)

Biocon’s most recent deal was a Secondary Transaction - Private with Ampin C&I Power Twelve for . The deal was made on 10-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ampin C&I Power Twelve 10-Jun-2026 Secondary Transaction - Private Energy Production
Pro-zeal Green Power Sixteen 31-Jan-2026 Corporate Energy Infrastructure
Biocon Biologics 21-Jan-2026 Secondary Transaction - Private Drug Discovery
Eywa Pharma (New Jersey facility) 02-Sep-2023 Corporate Asset Purchase Buildings and Property
Mylan (Biosimilar Businesses) 29-Nov-2022 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 20 investments and acquisitions. Get the full list »

Biocon ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

27.39 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Biocon’s complete esg history, request access »

Biocon Exits (2)

Biocon’s most recent exit was on 30-Sep-2009 from IDL Specialty Chemicals. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
IDL Specialty Chemicals 30-Sep-2009 Completed
axicorp 11-Feb-2008 Merger/Acquisition Completed
To view Biocon’s complete exits history, request access »

Biocon Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Syngene International Bangalore, India 1993
Biocon Biologics Bengaluru, India 1978

Biocon FAQs

  • When was Biocon founded?

    Biocon was founded in 1978.

  • Where is Biocon headquartered?

    Biocon is headquartered in Bengaluru, India.

  • What is the size of Biocon?

    Biocon has 9,811 total employees.

  • What industry is Biocon in?

    Biocon’s primary industry is Drug Discovery.

  • Is Biocon a private or public company?

    Biocon is a Public company.

  • What is Biocon’s stock symbol?

    The ticker symbol for Biocon is 532523.

  • What is the current stock price of Biocon?

    As of 19-Nov-2026 the stock price of Biocon is $3.88.

  • What is the current market cap of Biocon?

    The current market capitalization of Biocon is $6.35B.

  • What is Biocon’s current revenue?

    The trailing twelve month revenue for Biocon is $1.87B.

  • Who are Biocon’s competitors?

    Lupin, Cipla, GSK, Glenmark Pharmaceuticals, and Aurobindo Pharma are some of the 37 competitors of Biocon.

  • What is Biocon’s annual earnings per share (EPS)?

    Biocon’s EPS for 12 months was $0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process